Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two‐center experience
Clinical Transplantation2016Vol. 30(6), pp. 709–713
Citations Over TimeTop 10% of 2016 papers
Whitney E. Jackson, Mohamad Hanouneh, Tehilla Apfel, Naim Alkhouri, Binu V. John, Xaralambos Zervos, Nizar N. Zein, Ibrahim A. Hanouneh
Abstract
Sofosbuvir + SIM combination therapy without ribavirin is well tolerated and results in high virologic response rates in recurrent HCV GT1 infection after liver transplantation.
Related Papers
- → Simeprevir and Sofosbuvir for Treatment of Chronic Hepatitis C Infection(2015)33 cited
- Recent advances in the treatment of hepatitis C.(2014)
- → Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral–Experienced Patients With Hepatitis C(2017)19 cited
- → Treatment with Sofosbuvir + Simeprevir for 12 Weeks in HCV Compensated Cirrhosis (Genotypes 1 and 4); The Use of Ribavirin Does Not Influence Sustained Viral Response(2016)1 cited
- → Faculty Opinions recommendation of Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis.(2015)